drugset / Trial / NCT07516132
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Phase 3
Recruiting
850 enrolled
Ocular Therapeutix, Inc.
Duke Reading Center · collabFortrea · collab
NaSingle-groupOpen-labelTreatment
Summary
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Timeline
- Start
- 2026-04-27
- Primary completion
- 2030-08-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | Intravitreal |